Discussion forum for Pharma Quality events, Regulatory Actions

Warning letters, 483s, Recalls, Import Alerts, Audit observations

Biocon’s Biosimilar insulin Aspart rec

In a company announcement, Biocon informed that it has received a CR (Complete response) letter

Qvents
October 17, 2023

US eye drop manufacturer K.C. Pharmaceut

The USFDA Warning letter to K. C. Pharmaceuticals issued in August 2023, following inspection at

Qvents
August 30, 2023